Abstract
Background: Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods: we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results: our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions: Our findings support in clinical practice the 12-week schedule an alternative to the standard 4-week schedule in advanced breast and prostate cancer, in particular when the clinical comorbidities of the patients suggest a higher risk of renal failure or hypocalcaemia.
Original language | English |
---|---|
Pages (from-to) | 68-75 |
Number of pages | 8 |
Journal | Critical Reviews in Oncology/Hematology |
Volume | 142 |
DOIs | |
Publication status | Published - Oct 2019 |
Keywords
- AEs
- Bone metastases
- Breast
- Meta-Analysis
- Prostate
- SMR
- Solid tumors
- Zoledronic acid
ASJC Scopus subject areas
- Hematology
- Oncology